Ignite Creation Date:
2024-05-06 @ 7:04 PM
Last Modification Date:
2024-10-26 @ 3:00 PM
Study NCT ID:
NCT05888636
Status:
RECRUITING
Last Update Posted:
2024-03-22
First Post:
2023-03-24
Brief Title:
Transcriptomics and Epigenetics Analysis in Drug-Resistance of Multiple Myeloma
Sponsor:
Regina Elena Cancer Institute
Organization:
Regina Elena Cancer Institute
Study Overview
Official Title:
Transcriptomics and Epigenetics Analysis for Biomarkers Identification Involved in Drug-resistance Mechanisms of Multiple Myeloma
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TEDROMM
Brief Summary:
Multiple Myeloma MM is the more common hematological neoplastic disease second only to Hodgkin lymphoma In MM patients mutated genes are mainly KRAS 23 NRAS 20 FAM46C 11 DIS3 11 e TP53 8 Epigenetics studies suggested that Changes in histone modifications and DNA methylation pattern as well as non-coding RNAs miRNAs expression are involved in MM development In particular it has been shown that the aberrant expression of different miRNAs could discriminate healthy from ill patients Unfortunately the main critical issue for an effective treatment of MM is the intrinsic or acquired resistance to pharmacological treatments due also to a plasmacellular clonal heterogeneity
The prospective study will involve a patient cohort with MGUS MM smouldering and MM with the aim to characterize different transcriptional and epigenetic features also including miRNAs among MM cells susceptible or resistant to conventional therapies The final goal is to identify new prognostic and predictive biomarkers that could be used as therapeutic tools to improve clinical targeted therapies
The prospective study will involve a patient cohort with MGUS MM smouldering and MM with the aim to characterize different transcriptional and epigenetic features also including miRNAs among MM cells susceptible or resistant to conventional therapies The final goal is to identify new prognostic and predictive biomarkers that could be used as therapeutic tools to improve clinical targeted therapies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None